GenoFocus, Inc. (187420.KQ)
- Previous Close
3,835.00 - Open
3,835.00 - Bid --
- Ask --
- Day's Range
3,835.00 - 4,165.00 - 52 Week Range
2,800.00 - 6,150.00 - Volume
375,942 - Avg. Volume
108,821 - Market Cap (intraday)
89.159B - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
GenoFocus, Inc. engages in the research and development, production, sales, and import/export of enzymes and fermentation products in South Korea and internationally. Its products include industrial special enzyme including lactase intended for prevention of pathogen infection/proliferation and food poisoning, and prevention of allergies and atopy; proteinase K, a recombinant serine protease secreted from the fungal strain, Tritirachium album used for isolation of pure DNA from cultured cells and tissues, removal of DNase and RNase to isolate DNA and RNA from cells and tissues, and increase PRC cloning efficiency; and catalase, a hydrogen peroxide decomposing enzyme used in semiconductor water treatment, textile process, HPPO manufacturing process, etc. The company also offers bio-health care ingredient, such as N-phytosphingosine, a cosmetic material to help improve skin barrier function; and vitamin K2 for bone and cardiovascular health benefits. In addition, the company is developing superoxide dismutase, an antioxidant enzyme that is in preclinical trial. GenoFocus, Inc. was incorporated in 2000 and is based in Daejeon, South Korea.
www.genofocus.com--
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Related News
Performance Overview: 187420.KQ
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 187420.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 187420.KQ
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.92%
Return on Assets (ttm)
-5.10%
Return on Equity (ttm)
-2.34%
Revenue (ttm)
27.01B
Net Income Avi to Common (ttm)
-2.95B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
29.87B
Total Debt/Equity (mrq)
211.66%
Levered Free Cash Flow (ttm)
-22.12B